Velcade Intravenous 1,0 mg/ 3,5 mg Injection, powder
PDF Leaflet Revision Date: 23 January 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of multiple myeloma and mantle cell lymphoma.
Dosage (summary)
1.3 mg/mu00b2 IV twice weekly for 2 weeks, followed by a 10-day rest.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not established; contraindicated in breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Oral antidiabetic agents
Contraindications
- Hypersensitivity
- Acute pulmonary disease
Common side effects
- Nausea
- Diarrhoea
- Fatigue
- Thrombocytopenia
- Peripheral neuropathy
Counselling Points
- Monitor for signs of neuropathy
- Avoid driving if experiencing dizziness
- Use effective contraception during treatment.
Serious warnings
- Risk of intrathecal administration
- Herpes zoster reactivation
- Cardiac failure
Important Disclaimer
The Velcade Intravenous 1,0 mg/ 3,5 mg Injection, powder professional information leaflet below is the property of Janssen Pharmaceutica (Pty) Ltd and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
